{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T20:40:50Z","timestamp":1773261650711,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Oral Health"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Leukocyte- and platelet-rich fibrin (L-PRF) is an autologous matrix scaffold which regulates inflammation by stimulating cytokines and growth factors that are involved in the immune response. L-PRF is suggested as a viable adjunctive method to surgical interventions due to its advantages on tissue healing. This study aims to retrospectively evaluate the adjunctive role of L-PRF in surgically treated medication-related osteonecrosis of the jaws (MRONJ) patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Between January 2012 and December 2020, patients with AAOMS stage II and III MRONJ lesions, who were treated surgically with adjunctive use of L-PRF in the authors\u2019 institution were enrolled. Surgical interventions consisted of either marginal resection or\u00a0sequestrectomy with peripheral ostectomy (SPO) or curettage and L-PRF application. Medical records of these patients were retrospectively reviewed and healing was assessed according to certain parameters including mucosal closure and presence of infection, exposed bone, fistula or radiologic markers of disease progression for a minimum of 12 months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Thirteen patients (7 women and 6 men) with an average age of 72.4\u00a0years (\u00b1\u200910.61, range 54\u201384) were included in the study, nine of whom had AAOMS stage III and four stage II MRONJ. Three patients had a marginal resection, nine patients had sequestrectomy with peripheral ostectomy (SPO) and one patient underwent a curettage procedure. All marginal resection and six SPO patients showed complete healing while four patients, who had SPO or curettage experienced incomplete healing. Mean follow up was 20.1\u2009\u00b1\u200918.29\u00a0months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The use of L-PRF may be a favorable adjunctive option in the treatment of MRONJ owing to its favorable effects on tissue repair, ease of application, minimally invasive and cost-effective character and autogenous nature.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic> Retrospectively registered.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12903-021-01965-7","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T10:03:02Z","timestamp":1638352982000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Promising results of surgical management of advanced medication related osteonecrosis of the jaws using adjunctive leukocyte and platelet rich fibrin"],"prefix":"10.1186","volume":"21","author":[{"given":"\u00d6znur","family":"\u00d6zalp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nelli","family":"Y\u0131ld\u0131r\u0131myan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Canan","family":"\u00d6zt\u00fcrk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Burak","family":"Kocabalkan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00f6ksel","family":"\u015eim\u015fek Kaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alper","family":"Sindel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet Ali","family":"Altay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,1]]},"reference":[{"key":"1965_CR1","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","volume":"61","author":"RE Marx","year":"2003","unstructured":"Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61:1115\u20137.","journal-title":"J Oral Maxillofac Surg"},{"key":"1965_CR2","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/odi.12708","volume":"24","author":"K McGowan","year":"2018","unstructured":"McGowan K, McGowan T, Ivanovski S. Risk factors for medication-related osteonecrosis of the jaws: a systematic review. Oral Dis. 2018;24:527\u201336.","journal-title":"Oral Dis"},{"key":"1965_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbmr.2405","volume":"30","author":"AA Khan","year":"2015","unstructured":"Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O\u2019Ryan F, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015;30:3\u201323.","journal-title":"J Bone Miner Res"},{"key":"1965_CR4","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","volume":"72","author":"SL Ruggiero","year":"2014","unstructured":"Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw\u20142014 update. J Oral Maxillofac Surg. 2014;72:1938\u201356.","journal-title":"J Oral Maxillofac Surg"},{"key":"1965_CR5","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S1532-3382(12)70046-5","volume":"12","author":"J Yamashita","year":"2012","unstructured":"Yamashita J, McCauley LK. Antiresorptives and osteonecrosis of the jaw. J Evid Based Dent Pract. 2012;12:233\u201347.","journal-title":"J Evid Based Dent Pract"},{"key":"1965_CR6","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.tripleo.2006.06.004","volume":"102","author":"SL Ruggiero","year":"2006","unstructured":"Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endodont. 2006;102:433\u201341.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endodont"},{"key":"1965_CR7","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.critrevonc.2006.12.005","volume":"62","author":"R Weitzman","year":"2007","unstructured":"Weitzman R, Sauter N, Eriksen EF, Tarassoff PG, Lacerna LV, Dias R, et al. Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients\u2014May 2006. Crit Rev Oncol Hematol. 2007;62:148\u201352.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1965_CR8","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.oraloncology.2014.08.016","volume":"50","author":"K Rupel","year":"2014","unstructured":"Rupel K, Ottaviani G, Gobbo M, Contardo L, Tirelli G, Vescovi P, et al. A systematic review of therapeutical approaches in bisphosphonates-related osteonecrosis of the jaw (BRONJ). Oral Oncol. 2014;50:1049\u201357.","journal-title":"Oral Oncol"},{"key":"1965_CR9","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/ID.0b013e3182310f03","volume":"20","author":"CYS Lee","year":"2011","unstructured":"Lee CYS, Pien FD, Suzuki JB. Identification and treatment of bisphosphonate-associated actinomycotic osteonecrosis of the jaws. Implant Dent. 2011;20:331\u20136.","journal-title":"Implant Dent"},{"key":"1965_CR10","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/annonc\/mdn526","volume":"20","author":"CI Ripamonti","year":"2008","unstructured":"Ripamonti CI, Maniezzo M, Campa T, Fagnoni E, Brunelli C, Saibene G, et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Annals Oncol. 2008;20:137\u201345.","journal-title":"Annals Oncol."},{"key":"1965_CR11","first-page":"1741","volume":"16","author":"A Agrillo","year":"2012","unstructured":"Agrillo A, Filiaci F, Ramieri V, Riccardi E, Quarato D, Rinna C, et al. Bisphosphonate-related osteonecrosis of the jaw (BRONJ): 5 year experience in the treatment of 131 cases with ozone therapy. Eur Rev Med Pharmacol Sci. 2012;16:1741\u20137.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"1965_CR12","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1002\/jbmr.3237","volume":"32","author":"J Jung","year":"2017","unstructured":"Jung J, Yoo H-Y, Kim G-T, Lee J-W, Lee Y-A, Kim D-Y, et al. Short-term teriparatide and recombinant human bone morphogenetic protein-2 for regenerative approach to medication-related osteonecrosis of the jaw: a preliminary study. J Bone Miner Res. 2017;32:2445\u201352.","journal-title":"J Bone Miner Res"},{"key":"1965_CR13","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1056\/NEJMoa1005361","volume":"363","author":"JD Bashutski","year":"2010","unstructured":"Bashutski JD, Eber RM, Kinney JS, Benavides E, Maitra S, Braun TM, et al. Teriparatide and osseous regeneration in the oral cavity. New Engl J Med. 2010;363:2396\u2013405.","journal-title":"New Engl J Med"},{"key":"1965_CR14","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMc1002684","volume":"363","author":"A Cheung","year":"2010","unstructured":"Cheung A, Seeman E. Teriparatide therapy for alendronate-associated osteonecrosis of the jaw. New Eng J Med. 2010;363:2473\u20134.","journal-title":"New Eng J Med"},{"key":"1965_CR15","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.bjoms.2014.07.256","volume":"52","author":"J-W Kim","year":"2014","unstructured":"Kim J-W, Kim S-J, Kim M-R. Leucocyte-rich and platelet-rich fibrin for the treatment of bisphosphonate-related osteonecrosis of the jaw: a prospective feasibility study. Brit J Oral Max Sur. 2014;52:854\u20139.","journal-title":"Brit J Oral Max Sur"},{"key":"1965_CR16","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.joms.2013.07.027","volume":"72","author":"SS Soydan","year":"2014","unstructured":"Soydan SS, Uckan S. Management of bisphosphonate-related osteonecrosis of the jaw with a platelet-rich fibrin membrane: technical report. J Oral Maxillofac Surg. 2014;72:322\u20136.","journal-title":"J Oral Maxillofac Surg"},{"key":"1965_CR17","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1016\/j.joms.2011.02.078","volume":"69","author":"MM Curi","year":"2011","unstructured":"Curi MM, Cossolin GSI, Koga DH, Zardetto C, Christianini S, Feher O, et al. Bisphosphonate-related osteonecrosis of the jaws\u2013an initial case series report of treatment combining partial bone resection and autologous platelet-rich plasma. J Oral Maxillofac Surg. 2011;69:2465\u201372.","journal-title":"J Oral Maxillofac Surg"},{"key":"1965_CR18","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1016\/j.tripleo.2005.07.011","volume":"101","author":"J Choukroun","year":"2006","unstructured":"Choukroun J, Diss A, Simonpieri A, Girard M-O, Schoeffler C, Dohan SL, et al. Platelet-rich fibrin (PRF): a second-generation platelet concentrate, part IV: clinical effects on tissue healing. Oral Surg Oral Med Oral Pathol Oral Radiol Endodont. 2006;101:e56\u201360.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endodont"},{"key":"1965_CR19","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.oooo.2016.06.019","volume":"122","author":"AA Owosho","year":"2016","unstructured":"Owosho AA, Estilo CL, Huryn JM, Yom SK. Pentoxifylline and tocopherol in the management of cancer patients with medication-related osteonecrosis of the jaw: an observational retrospective study of initial case series. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;122:455\u20139.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"1965_CR20","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.tibtech.2008.11.009","volume":"27","author":"DM Dohan Ehrenfest","year":"2009","unstructured":"Dohan Ehrenfest DM, Rasmusson L, Albrektsson T. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). Trends Biotechnol. 2009;27:158\u201367.","journal-title":"Trends Biotechnol"},{"key":"1965_CR21","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3389\/fsurg.2020.537138","volume":"7","author":"M Damsaz","year":"2020","unstructured":"Damsaz M, Castagnoli CZ, Eshghpour M, Alamdari DH, Alamdari AH, Noujeim ZEF, et al. Evidence-based clinical efficacy of leukocyte and platelet-rich fibrin in maxillary sinus floor lift, graft and surgical augmentation procedures. Front Surg. 2020;7:83.","journal-title":"Front Surg"},{"key":"1965_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s10006-015-0538-x","volume":"20","author":"LF Silva","year":"2016","unstructured":"Silva LF, Curra C, Munerato MS. Surgical management of bisphosphonate-related osteonecrosis of the jaws: literature review. J Oral Maxillofac Surg. 2016;20:9\u201317.","journal-title":"J Oral Maxillofac Surg"},{"key":"1965_CR23","first-page":"111","volume":"55","author":"Z Janovsk\u00e1","year":"2012","unstructured":"Janovsk\u00e1 Z. Bisphosphonate-related osteonecrosis of the jaws: a severe side effect of bisphosphonate therapy. Acta Medica. 2012;55:111\u20135.","journal-title":"Acta Medica"},{"key":"1965_CR24","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.oraloncology.2013.05.012","volume":"49","author":"MA Lerman","year":"2013","unstructured":"Lerman MA, Xie W, Treister NS, Richardson PG, Weller EA, Woo S-B. Conservative management of bisphosphonate-related osteonecrosis of the jaws: staging and treatment outcomes. Oral Oncol. 2013;49:977\u201383.","journal-title":"Oral Oncol"},{"key":"1965_CR25","first-page":"e302","volume":"9","author":"A Comas-Calonge","year":"2017","unstructured":"Comas-Calonge A, Figueiredo R, Gay-Escoda C. Surgical treatment vs conservative treatment in intravenous bisphosphonate-related osteonecrosis of the jaws. Systematic review. J Clin Exp Dent. 2017;9:e302.","journal-title":"J Clin Exp Dent"},{"key":"1965_CR26","doi-asserted-by":"publisher","first-page":"584-94.e2","DOI":"10.1016\/j.adaj.2017.04.002","volume":"148","author":"M El-Rabbany","year":"2017","unstructured":"El-Rabbany M, Sgro A, Lam DK, Shah PS, Azarpazhooh A. Effectiveness of treatments for medication-related osteonecrosis of the jaw: a systematic review and meta-analysis. J Am Dent Assoc. 2017;148:584-94.e2.","journal-title":"J Am Dent Assoc"},{"key":"1965_CR27","first-page":"e1051","volume":"9","author":"JA Cano-Dur\u00e1n","year":"2017","unstructured":"Cano-Dur\u00e1n JA, Pe\u00f1a-Cardelles JF, Ortega-Concepci\u00f3n D, Paredes-Rodr\u00edguez VM, Garc\u00eda-Riart M, L\u00f3pez-Quiles J. The role of Leucocyte-rich and platelet-rich fibrin (L-PRF) in the treatment of the medication-related osteonecrosis of the jaws (MRONJ). J Clin Exp Dent. 2017;9:e1051\u20139.","journal-title":"J Clin Exp Dent"},{"key":"1965_CR28","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.1600-0765.2006.00892.x","volume":"41","author":"H Goto","year":"2006","unstructured":"Goto H, Matsuyama T, Miyamoto M, Yonamine Y, Izumi Y. Platelet-rich plasma\/osteoblasts complex induces bone formation via osteoblastic differentiation following subcutaneous transplantation. J Periodont Res. 2006;41:455\u201362.","journal-title":"J Periodont Res"},{"key":"1965_CR29","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.2174\/138920112800624337","volume":"13","author":"M Zumstein","year":"2012","unstructured":"Zumstein M, Berger S, Schober M, Boileau P, Nyffeler R, Horn M, et al. Leukocyte-and platelet-rich fibrin (L-PRF) for long-term delivery of growth factor in rotator cuff repair: review, preliminary results and future directions. Curr Pharm Biotechnol. 2012;13:1196\u2013206.","journal-title":"Curr Pharm Biotechnol"},{"key":"1965_CR30","first-page":"47","volume":"1","author":"F Bastami","year":"2016","unstructured":"Bastami F, Khojasteh A. Use of leukocyte-and platelet-rich fibrin for bone regeneration: a systematic review. Regener Reconstruct Restorat. 2016;1:47\u201368.","journal-title":"Regener Reconstruct Restorat"},{"key":"1965_CR31","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1016\/j.joms.2016.12.005","volume":"75","author":"J-H Park","year":"2017","unstructured":"Park J-H, Kim J-W, Kim S-J. Does the addition of bone morphogenetic protein 2 to platelet-rich fibrin improve healing after treatment for medication-related osteonecrosis of the jaw? J Oral Maxillofac Surg. 2017;75:1176\u201384.","journal-title":"J Oral Maxillofac Surg"},{"key":"1965_CR32","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1590\/0103-6440201600662","volume":"27","author":"G Maluf","year":"2016","unstructured":"Maluf G, Pinho MC, Cunha SRB, Santos PSS, Fregnani ER. Surgery combined with LPRF in denosumab osteonecrosis of the jaw: case report. Braz Dent J. 2016;27:353\u20138.","journal-title":"Braz Dent J"},{"key":"1965_CR33","doi-asserted-by":"publisher","first-page":"115676","DOI":"10.1016\/j.bone.2020.115676","volume":"2020","author":"D Govaerts","year":"2020","unstructured":"Govaerts D, Piccart F, Ockerman A, Coropciuc R, Politis C, Jacobs R. Adjuvant therapies for MRONJ: a systematic review. Bone. 2020;2020:115676.","journal-title":"Bone"},{"key":"1965_CR34","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jcms.2020.01.014","volume":"48","author":"L Fortunato","year":"2020","unstructured":"Fortunato L, Bennardo F, Buffone C, Giudice A. Is the application of platelet concentrates effective in the prevention and treatment of medication-related osteonecrosis of the jaw? A systematic review. J Craniomaxillofac Surg. 2020;48:268\u201385.","journal-title":"J Craniomaxillofac Surg"},{"key":"1965_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jormas.2021.01.015","author":"M Escobedo","year":"2021","unstructured":"Escobedo M, Junquera S, Gonzalez C, Vasatyuk S, Gallego L, Barbeito E, et al. Efficacy of complementary treatment with autologous platelet concentrates and\/or mesenchymal stem cells in chemical osteonecrosis of the jaw. Systematic review of the literature. J Stomatol Oral Maxillofac Surg. 2021. https:\/\/doi.org\/10.1016\/j.jormas.2021.01.015.","journal-title":"J Stomatol Oral Maxillofac Surg"},{"key":"1965_CR36","first-page":"1","volume":"2018","author":"L Ramaglia","year":"2018","unstructured":"Ramaglia L, Guida A, Iorio-Siciliano V, Cuozzo A, Blasi A, Sculean A. Stage-specific therapeutic strategies of medication-related osteonecrosis of the jaws: a systematic review and meta-analysis of the drug suspension protocol. Clin Oral Investig. 2018;2018:1\u201319.","journal-title":"Clin Oral Investig"},{"key":"1965_CR37","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1089\/ten.tea.2010.0327","volume":"17","author":"Y-H Kang","year":"2011","unstructured":"Kang Y-H, Jeon SH, Park J-Y, Chung J-H, Choung Y-H, Choung H-W, et al. Platelet-rich fibrin is a Bioscaffold and reservoir of growth factors for tissue regeneration. Tissue Eng Part A. 2011;17:349\u201359.","journal-title":"Tissue Eng Part A"},{"key":"1965_CR38","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.2174\/138920112800624391","volume":"13","author":"M Del Corso","year":"2012","unstructured":"Del Corso M, Vervelle A, Simonpieri A, Jimbo R, Inchingolo F, Sammartino G, et al. Current knowledge and perspectives for the use of platelet-rich plasma (PRP) and platelet-rich fibrin (PRF) in oral and maxillofacial surgery part 1: Periodontal and dentoalveolar surgery. Curr Pharm Biotechnol. 2012;13:1207\u201330.","journal-title":"Curr Pharm Biotechnol"},{"key":"1965_CR39","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.2174\/138920112800624472","volume":"13","author":"A Simonpieri","year":"2012","unstructured":"Simonpieri A, Del Corso M, Vervelle A, Jimbo R, Inchingolo F, Sammartino G, et al. Current knowledge and perspectives for the use of platelet-rich plasma (PRP) and platelet-rich fibrin (PRF) in oral and maxillofacial surgery part 2: Bone graft, implant and reconstructive surgery. Curr Pharm Biotechnol. 2012;13:1231\u201356.","journal-title":"Curr Pharm Biotechnol"}],"container-title":["BMC Oral Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12903-021-01965-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12903-021-01965-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12903-021-01965-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T10:03:34Z","timestamp":1638353014000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcoralhealth.biomedcentral.com\/articles\/10.1186\/s12903-021-01965-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1965"],"URL":"https:\/\/doi.org\/10.1186\/s12903-021-01965-7","relation":{},"ISSN":["1472-6831"],"issn-type":[{"value":"1472-6831","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"11 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was gained from the Akdeniz University\u2019s Ethical Review Board (Protocol: 664\/26.09.2018). All patients gave informed written consent to have treatment in Faculty of Dentistry of Akdeniz University and no administrative permissions or licenses were required to access patient records.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"613"}}